Hypertrophic Cardiomyopathy After Braunwald
Decision brief
Answer first · skim in under a minute
The Pulse of ACC commemorates the indelible legacy of Dr. Eugene Braunwald, widely recognized as the father of modern cardiology, particularly for his foundational work in hypertrophic cardiomyopathy. The article also serves as a call for community feedback to guide the future direction of cardiovascular medicine.
Hypertrophic cardiomyopathy remains the clearest commercial bridge from Eugene Braunwald’s science to today’s pipelines. After his death on April 22, 2026, ACC-facing agendas still orbit the disease biology he helped define—and the drugs now treating obstruction.
Contents10 sections
Key Takeaways
- Eugene Braunwald died April 22, 2026, at age 96; tributes from Harvard Medical School and cardiology societies framed him as a founder of modern cardiology.
- FDA approved Camzyos (mavacamten) for symptomatic NYHA II–III obstructive hypertrophic cardiomyopathy to improve exercise capacity and symptoms.
- In the 30-week pivotal study FDA summarized, 37% of Camzyos patients improved on the composite endpoint versus 17% on placebo.
- Pipeline teams should treat HCM as a continuing myosin-biology franchise, not a one-drug story.
What is hypertrophic cardiomyopathy in clinical terms?
Hypertrophic cardiomyopathy (HCM) thickens heart muscle, often the septum, and can obstruct outflow. FDA’s Camzyos approval notice describes obstructive HCM as a rare disease that can cause palpitations, shortness of breath, leg swelling, and reduced exercise capacity.
NovaPharma’s disease hub on hypertrophic cardiomyopathy tracks related assets and news. For primary disease framing, the NHLBI cardiomyopathy overview remains a patient-facing federal reference on cardiomyopathy types and care basics.
How did Braunwald shape the HCM research agenda?
Braunwald’s career linked pathophysiology, large trials, and mentoring networks that still staff ACC programs. Contemporary reviews on PMC summarize decades of HCM science that grew from that era’s invasive hemodynamics and natural-history cohorts.
For pharma strategy, the point is simple. When ACC membership debates priorities, HCM sits where mechanism, imaging endpoints, and specialty centers already exist. That lowers the cost of running differentiated trials versus starting a new disease franchise from zero.
What did FDA’s Camzyos decision change?
In April 2022, FDA approved Camzyos (mavacamten) capsules for adults with symptomatic NYHA class II–III obstructive HCM to improve exercise capacity and symptoms, per the FDA approval announcement.
FDA reported that after 30 weeks, 37% of participants on Camzyos improved on an endpoint combining exercise capacity and symptoms, versus 17% on placebo. The agency also warned that the drug can weaken contraction and cause heart failure, which is why REMS monitoring remains central to uptake models.
Where should competitors and BD teams look next?
Camzyos proved cardiac myosin inhibition can be a commercial class. Follow-on oral myosin inhibitors, combination strategies, and earlier-line use will set the next valuation debates. Device and septal-reduction pathways still matter for patients who fail or cannot take medical therapy.
- Compare NYHA class mix and LVOT gradient entry criteria across trials.
- Model REMS and echo burden as real commercial costs, not footnotes.
- Watch Asia regulatory timelines for the same mechanism class.
- Track Edgewise and other HCM pipelines against Camzyos durability data.
Related coverage includes Edgewise’s CIRRUS-HCM work at Edgewise EDG-7500 Phase 2 CIRRUS-HCM.
What remains unproven
Tributes do not move share prices. Neither do ACC community polls by themselves. Unproven items include long-term class durability beyond Camzyos’s pivotal window, non-obstructive HCM benefit for myosin inhibitors, and whether gene-targeted approaches can clear safety bars in larger cohorts.
APAC implications for hypertrophic cardiomyopathy programs
Asia-Pacific cardiology centers already run echo-heavy specialty clinics that can support myosin-inhibitor monitoring. That capacity is an under-discussed commercial asset. Sponsors entering Japan, South Korea, Australia, or Singapore should budget for REMS-like echo cadence even when local labels differ from the U.S. REMS text.
Trial planners should also decide early whether Asia sites will contribute primary efficacy subjects or only extension cohorts. Hypertrophic cardiomyopathy enrollment is slow when LVOT gradient and NYHA filters are strict. Multi-country Asia protocols can shorten calendar time if imaging quality and genotype panels are harmonized up front.
Investors comparing HCM assets should ask for Asia contribution tables in every Phase 2 and Phase 3 readout: how many randomized patients, how many echo-evaluable patients, and how adverse-event rates differ by region. Those details matter more than tribute essays when modeling peak sales after 2026.
Related NovaPharma coverage
- Hypertrophic cardiomyopathy disease hub
- Edgewise Therapeutics EDG-7500 Phase 2 CIRRUS-HCM
- Blood pressure, ischemic stroke risk, and dementia cohort
Frequently Asked Questions
What is hypertrophic cardiomyopathy?
Hypertrophic cardiomyopathy is a disease in which the heart muscle thickens, often in the septum, and can obstruct blood flow out of the left ventricle. Symptoms can include shortness of breath, reduced exercise capacity, palpitations, and swelling of the legs.
What did FDA approve for obstructive HCM?
FDA approved Camzyos (mavacamten) for adults with symptomatic NYHA class II–III obstructive hypertrophic cardiomyopathy to improve exercise capacity and symptoms. In the pivotal study, 37% of Camzyos-treated participants improved on a composite exercise and symptom endpoint versus 17% on placebo after 30 weeks.
Why does Braunwald’s legacy matter for pipeline strategy?
Braunwald helped define the pathophysiology and trial culture that still guides HCM research priorities. Pharma teams should map myosin-inhibitor follow-ons, gene-targeted approaches, and device strategies against that evidence base rather than against conference slogans alone.
Primary Sources
Sources & references 1 primary sources
Sources verified at publication. See our editorial policy and data sources.
This article follows our editorial standards. Report a correction via editorial contact.
